TransMedics Group (NASDAQ:TMDX) Stock Rating Upgraded by Wall Street Zen

TransMedics Group (NASDAQ:TMDX) was upgraded by stock analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Sunday.

TMDX has been the subject of a number of other reports. Needham & Company LLC upped their price objective on shares of TransMedics Group from $148.00 to $166.00 and gave the company a “buy” rating in a research note on Monday, December 8th. Morgan Stanley boosted their price target on shares of TransMedics Group from $123.00 to $135.00 and gave the company an “equal weight” rating in a report on Tuesday, December 2nd. Evercore ISI initiated coverage on shares of TransMedics Group in a research report on Tuesday, September 16th. They issued an “outperform” rating and a $155.00 price target for the company. Zacks Research cut shares of TransMedics Group from a “strong-buy” rating to a “hold” rating in a research report on Monday, October 6th. Finally, Canaccord Genuity Group boosted their target price on shares of TransMedics Group from $147.00 to $148.00 and gave the company a “buy” rating in a research note on Wednesday, December 17th. Six research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $144.25.

TransMedics Group Stock Down 2.2%

NASDAQ TMDX opened at $124.20 on Friday. TransMedics Group has a 12 month low of $55.00 and a 12 month high of $156.00. The company has a market capitalization of $4.24 billion, a P/E ratio of 50.28 and a beta of 2.06. The company’s 50 day simple moving average is $129.07 and its 200 day simple moving average is $122.62. The company has a debt-to-equity ratio of 1.43, a current ratio of 7.69 and a quick ratio of 7.13.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings data on Wednesday, October 29th. The company reported $0.66 earnings per share for the quarter, topping the consensus estimate of $0.37 by $0.29. The business had revenue of $143.82 million during the quarter, compared to analyst estimates of $145.33 million. TransMedics Group had a return on equity of 31.42% and a net margin of 16.20%.The company’s revenue was up 32.2% compared to the same quarter last year. During the same period last year, the company posted $0.12 EPS. Equities research analysts expect that TransMedics Group will post 1 earnings per share for the current fiscal year.

Insider Transactions at TransMedics Group

In other TransMedics Group news, Director Edward M. Basile sold 4,142 shares of TransMedics Group stock in a transaction that occurred on Wednesday, October 29th. The shares were sold at an average price of $130.45, for a total value of $540,323.90. Following the completion of the sale, the director directly owned 2,866 shares in the company, valued at $373,869.70. The trade was a 59.10% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Gerardo Hernandez sold 920 shares of the stock in a transaction dated Thursday, December 4th. The shares were sold at an average price of $139.62, for a total value of $128,450.40. Following the transaction, the chief financial officer directly owned 15,064 shares in the company, valued at approximately $2,103,235.68. This represents a 5.76% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 13,062 shares of company stock valued at $1,797,634 over the last 90 days. Company insiders own 7.00% of the company’s stock.

Hedge Funds Weigh In On TransMedics Group

Several hedge funds have recently added to or reduced their stakes in the company. Amalgamated Bank boosted its stake in TransMedics Group by 0.8% in the 2nd quarter. Amalgamated Bank now owns 9,586 shares of the company’s stock worth $1,285,000 after purchasing an additional 80 shares during the period. Canada Pension Plan Investment Board boosted its position in TransMedics Group by 2.9% during the 2nd quarter. Canada Pension Plan Investment Board now owns 3,600 shares of the company’s stock worth $482,000 after acquiring an additional 100 shares during the last quarter. US Bancorp DE boosted its position in TransMedics Group by 24.2% during the 3rd quarter. US Bancorp DE now owns 533 shares of the company’s stock worth $60,000 after acquiring an additional 104 shares during the last quarter. Smartleaf Asset Management LLC grew its stake in shares of TransMedics Group by 24.5% during the 2nd quarter. Smartleaf Asset Management LLC now owns 548 shares of the company’s stock worth $72,000 after acquiring an additional 108 shares in the last quarter. Finally, Allworth Financial LP raised its holdings in shares of TransMedics Group by 74.3% in the third quarter. Allworth Financial LP now owns 265 shares of the company’s stock valued at $30,000 after purchasing an additional 113 shares during the last quarter. Institutional investors own 99.67% of the company’s stock.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.